News

Long-term treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) led to significant gains in lung function and nutritional status for cystic fibrosis (CF) patients with advanced lung disease, a real-world analysis shows. The improvements weren’t as large as those seen in patients with milder lung disease, but the findings demonstrate the…

Lung function decline slowed consistently over five years with Kalydeco (ivacaftor) treatment in adults and children with cystic fibrosis (CF), a real-world study in the U.S. shows. “Overall, these results expand on those from prior studies and show that [Kalydeco] has a meaningful and sustained impact on reducing…

The Cystic Fibrosis Foundation has awarded $3 million to support a study of mental health among young children with cystic fibrosis (CF) to University at Buffalo (UB) researcher Beth A. Smith, MD, a psychiatrist whose work in this area has already helped to get new screening programs into…

About half of cystic fibrosis (CF) patients had used, were using, or were interested in using cannabidiol (CBD), the main active compounds found in the cannabis plant, according to a new survey and analysis conducted at a U.S. center. “Cannabidiol is used to treat a variety of symptoms including…

More severe lung disease and using inhaled corticosteroids are associated with shorter telomere length, a sign of cellular aging, in immune cells from people with cystic fibrosis (CF), a study suggests. Telomeres are stretches of repetitive DNA that protect the ends of chromosomes, the long strings of DNA that…

Most people with cystic fibrosis (CF) who carry mutations that make them ineligible for CFTR modulators are prescribed medications that improve mucus thinning and clearance. Antibiotic use is also high, and because most patients had pancreatic insufficiency, treatment with pancreatic enzyme replacement therapy is also common. That’s according…

Having COVID-19 had no clinically meaningful impact on lung function and nutritional status for people with cystic fibrosis in the year after an infection, a study across 33 countries indicates. According to the researchers, the “study is [a] global representation of the impact of COVID-19 on the health of…

Claire’s Place Foundation is gearing up to celebrate its 10th Annual Glow Ride for Cystic Fibrosis (CF) that’s set to happen Sept. 21 at Hermosa Beach, California. The milestone event aims to raise crucial funds to…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) cut sweat chloride levels in half among people with cystic fibrosis (CF), according to a real-world Danish study. Still, sweat chloride levels — a known biomarker of treatment responses in CF — were variable, and some treated patients still had levels out of the…

The Rare Disease Cures Accelerator-Data and Analytics Platform — dubbed RDCA–DAP — has received new datasets that promise to accelerate research and the development of new therapies for cystic fibrosis (CF). The data was generated by the Cystic Fibrosis Therapeutics Development Network (TDN), known for its clinical trials…